Compare FIRY & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIRY | MOLN |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.9M | 147.5M |
| IPO Year | 2020 | 2021 |
| Metric | FIRY | MOLN |
|---|---|---|
| Price | $11.51 | $3.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.36 |
| AVG Volume (30 Days) | ★ 149.9K | 2.0K |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $104,496,000.00 | N/A |
| Revenue This Year | $22.11 | N/A |
| Revenue Next Year | $7.99 | $450.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.52 | N/A |
| 52 Week Low | $7.92 | $3.52 |
| 52 Week High | $14.12 | $5.36 |
| Indicator | FIRY | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 49.14 | 36.40 |
| Support Level | $9.31 | N/A |
| Resistance Level | $14.02 | $4.59 |
| Average True Range (ATR) | 0.66 | 0.13 |
| MACD | -0.18 | -0.04 |
| Stochastic Oscillator | 35.29 | 5.13 |
Firy Inc, formerly Skillz Inc is a two-sided mobile gaming platform that connects developers with competitive players. Its reportable segments are: the Skillz segment and the RZR segment. Skillz segment's highlights include Monetize Through Competitions, Player Matching, Cross-Platform Support, Comprehensive Analytics, and Focus on Game Development. Aarki is a performance marketing platform that enables advertisers to acquire, retain, and monetize users across mobile, connected television (CTV), and other digital channels. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube, among others. It generates the majority of its revenue from the Skillz segment. Geographically, the company derives its key revenue from the United States.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.